niacinamide has been researched along with Rectal Neoplasms in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Rectal Neoplasms: Tumors or cancer of the RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "With the changed dosing schedule, this regimen was very well tolerated." | 6.82 | Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. ( Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X, 2016) |
| "10 mmol/kg) and carbogen breathing, administered alone or in combination, were investigated on two tumour cell lines: EMT6 (a rodent mammary carcinoma) and HRT18 (a human rectal adenocarcinoma) using a clonogenic assay." | 3.69 | Efficacy of agents counteracting hypoxia in fractionated radiation regimes. ( Guichard, M; Stern, S, 1996) |
| "With the changed dosing schedule, this regimen was very well tolerated." | 2.82 | Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. ( Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X, 2016) |
| " Pharmacokinetic sampling was performed in all patients; preliminary tumor response was also assessed." | 2.71 | Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. ( Awada, A; Brendel, E; Faghih, M; Haase, CG; Hilger, RA; Korfee, S; Richly, H; Scheulen, ME; Schleucher, N; Schwartz, B; Seeber, S; Strumberg, D; Tewes, M; Voigtmann, R; Voliotis, D, 2005) |
| " The aim was to establish the pharmacokinetic profiles and their reproducibility during repeated administration, the maximum tolerated dose with fractionated radiotherapy, whether such a dose achieves sufficiently high plasma levels for radiosensitization, the optimal time interval between nicotinamide and irradiation, and toxic side effects." | 2.68 | Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity. ( Dennis, MF; Hall, DW; Hoskin, PJ; Rojas, A; Saunders, MI; Stratford, MR, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| von Moos, R | 1 |
| Koeberle, D | 1 |
| Schacher, S | 1 |
| Hayoz, S | 1 |
| Winterhalder, RC | 1 |
| Roth, A | 1 |
| Bodoky, G | 1 |
| Samaras, P | 1 |
| Berger, MD | 1 |
| Rauch, D | 1 |
| Saletti, P | 1 |
| Plasswilm, L | 1 |
| Zwahlen, D | 1 |
| Meier, UR | 1 |
| Yan, P | 1 |
| Izzo, P | 1 |
| Klingbiel, D | 1 |
| Bärtschi, D | 1 |
| Zaugg, K | 1 |
| Kim, R | 1 |
| Prithviraj, GK | 1 |
| Shridhar, R | 1 |
| Hoffe, SE | 1 |
| Jiang, K | 1 |
| Zhao, X | 1 |
| Chen, DT | 1 |
| Almhanna, K | 1 |
| Strosberg, J | 1 |
| Campos, T | 1 |
| Shibata, D | 1 |
| Strumberg, D | 1 |
| Richly, H | 1 |
| Hilger, RA | 1 |
| Schleucher, N | 1 |
| Korfee, S | 1 |
| Tewes, M | 1 |
| Faghih, M | 1 |
| Brendel, E | 1 |
| Voliotis, D | 1 |
| Haase, CG | 1 |
| Schwartz, B | 1 |
| Awada, A | 1 |
| Voigtmann, R | 1 |
| Scheulen, ME | 1 |
| Seeber, S | 1 |
| Hoskin, PJ | 1 |
| Stratford, MR | 1 |
| Saunders, MI | 1 |
| Hall, DW | 1 |
| Dennis, MF | 1 |
| Rojas, A | 1 |
| Stern, S | 3 |
| Hodgkiss, RJ | 1 |
| Guichard, M | 3 |
| Thomas, CD | 1 |
| Chaplin, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neoadjuvant Radiotherapy Combined With Capecitabine and Sorafenib in Patients With Advanced, K-ras Mutated Rectal Cancer. A Multicenter Phase I/IIa Trial.[NCT00869570] | Phase 1/Phase 2 | 54 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Phase I Study of Pre-operative Continuous 5-FU, and Sorafenib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma[NCT01376453] | Phase 1 | 18 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Sorafenib Administered Using a High-dose, Pulsatile Regimen in Patients With Advanced Solid Malignancies: a Phase I Exposure Escalation Study[NCT02636426] | Phase 1 | 17 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors[NCT00933777] | Phase 1 | 36 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for niacinamide and Rectal Neoplasms
| Article | Year |
|---|---|
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2018 |
Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose | 2016 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity.
Topics: Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mouth Neop | 1995 |
3 other studies available for niacinamide and Rectal Neoplasms
| Article | Year |
|---|---|
Comparison of two techniques for detecting tumour hypoxia: a fluorescent immunochemical method and an in vitro colony assay.
Topics: Adenocarcinoma; Animals; Carbon Dioxide; Cell Hypoxia; Cell Survival; Cesium Radioisotopes; DNA Dama | 1996 |
Transient perfusion and radiosensitizing effect after nicotinamide, carbogen, and perflubron emulsion administration.
Topics: Adenocarcinoma; Animals; Carbon Dioxide; Emulsions; Female; Fluorocarbons; Humans; Hydrocarbons, Bro | 1996 |
Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
Topics: Adenocarcinoma; Animals; Carbon Dioxide; Cell Hypoxia; Emulsions; Female; Fluorocarbons; Humans; Hyd | 1996 |